Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry.
Daniele ArmeniaVincenzo SpagnuoloMaria C BellocchiLaura GalliLeonardo DucaGreta MarchegianiTommaso ClementeLuca CariotiRiccardo LolattoLeonardo CalzaBenedetto M CelesiaAntonio CascioDaniela FrancisciAnnalisa SaracinoCarlo TortiMaurizio ZazziAntonella CastagnaMaria-Mercedes Santoronull nullPublished in: The Journal of antimicrobial chemotherapy (2024)
In non-viraemic people with an MDR virus, HIV-1 DNA NGS set at 5% is an acceptable technical cut-off that might help to reveal mutations with a potential clinical relevance. Moreover, the number of minority resistance mutations additionally detected by NGS might be associated with loss of virological control.
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv positive
- human immunodeficiency virus
- multidrug resistant
- hiv testing
- hiv aids
- hiv infected patients
- circulating tumor
- hepatitis c virus
- men who have sex with men
- single molecule
- cell free
- south africa
- gene expression
- electronic health record
- big data
- circulating tumor cells
- machine learning
- risk assessment
- dna methylation
- copy number
- combination therapy
- single cell
- deep learning
- nucleic acid
- replacement therapy